Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-01-03 AGM Information
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Combined General Meeting of January 25, 2023 - Availability of the preparatory documents
AGM Information Classification · 98% confidence The document is titled "Combined General Meeting of January 25, 2023 Availability of the preparatory documents" and explicitly announces that the preparatory documents for the Combined General Meeting (AGM) are now available. It details the date and location of the meeting and references the publication of the preliminary notice of meeting. This content directly relates to the materials and announcements surrounding a shareholder meeting, fitting the definition of AGM Information (AGM-R). Although it announces the availability of documents, the core subject matter is the AGM itself, making AGM-R more specific than a general Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2023-01-03 English
Assemblée Générale Mixte du 25 janvier 2023 - Modalités de mise à disposition des documents préparatoires
AGM Information Classification · 98% confidence The document is titled "Assemblée Générale Mixte du 25 janvier 2023 Modalités de mise à disposition des documents préparatoires" and announces the procedures for making preparatory documents available for the Annual General Meeting (AGM) scheduled for January 25, 2023. It explicitly mentions the 'avis de réunion' (notice of meeting) and details how shareholders can consult or download the related documents. This content directly relates to the organization and materials surrounding the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). It is not a proxy statement (PSI) because it is an announcement about the availability of AGM documents, not the solicitation of votes itself, nor is it a Report Publication Announcement (RPA) as it is specifically about the AGM materials, not a general financial report.
2023-01-03 French
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate/financing event: drawing down a €25 million tranche under a Finance Contract with the European Investment Bank (EIB). This announcement details the receipt of funds, the conditions precedent met, and the intended use of proceeds (funding a Phase III clinical trial). This content aligns best with an announcement regarding financing activities or capital structure changes, which corresponds to the 'Capital/Financing Update' category (CAP). It is not a full financial report (10-K or IR), a transcript (CT), or a general regulatory filing (RNS), as it concerns a specific financing event.
2022-12-12 English
Inventiva annonce le tirage de la première tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate financial event: the drawing down of the first tranche (€25 million) of a financing agreement with the European Investment Bank (EIB). This type of announcement, detailing the receipt of funds, financing terms, and impact on cash runway, falls under corporate financing activities. The most appropriate category is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER) focusing on operational results, or a formal regulatory filing like a proxy statement. Since it is a detailed announcement about securing capital, CAP is the best fit over the general 'RNS' fallback.
2022-12-12 French
Inventiva obtient un nouveau brevet élargissant la protection de la propriété intellectuelle de son produit candidat phare lanifibranor aux États-Unis
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate event: obtaining a new patent for its drug candidate lanifibranor in the US. It details the patent number, expiration date, and the scientific implications. This format—a brief announcement of a specific, non-periodic corporate event (like a patent grant, management change, or M&A update)—is characteristic of a general regulatory announcement or press release. Since the definitions do not have a specific 'Patent Announcement' code, and it is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), the most appropriate general category for a non-standard, timely corporate disclosure is 'Regulatory Filings' (RNS), which serves as a fallback for miscellaneous announcements. It is not an Investor Presentation (IP) as it lacks the typical slide structure, nor is it a Legal Report (LTR) or a Financing Update (CAP). Given the content is a formal announcement of an IP development, RNS is the best fit among the provided options.
2022-11-28 French
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate event: securing a new patent for its lead product candidate, lanifibranor. It contains key highlights, quotes from management, and standard boilerplate sections about the company and forward-looking statements. This format is characteristic of an initial announcement of material, non-financial news, which typically falls under general regulatory announcements or press releases. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific legal/governance document, the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings), as it serves as a public disclosure of material information.
2022-11-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.